Experimental drug INCB000631 put to first safety test in humans
NCT ID NCT07039929
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and how the body handles the experimental drug INCB000631 in 24 healthy adults. Participants received either the drug or a placebo by mouth. The trial was terminated, so final results may not be available. It was not designed to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- INCB000631
- What could go wrong
- This is a very early, small study in healthy people, so it cannot show whether the drug works for any disease. The trial was terminated, meaning results may be incomplete.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celerion, Inc
Lincoln, Nebraska, 68502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates